Teva Pharmaceutical Industries Limited
TEVANYSEHealthcare● Active
$34.19
$-0.24(-0.70%)
Market Cap$39.8B
P/E Ratio—
52W High$37.35
52W Low$14.99
Teva Pharmaceutical Industries Limited (TEVA) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TEVA · as of 2026-06-08
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $1.42B | ($1.96B) | ($0.61B) | ($2.41B) | $0.46B |
| Depreciation & Amort. | $1.00B | $1.06B | $1.15B | $1.31B | $1.33B |
| Stock-Based Comp. | $0.16B | $0.12B | $0.12B | $0.12B | $0.12B |
| Change in Working Capital | ($1.37B) | ($0.43B) | ($0.07B) | $1.26B | ($1.70B) |
| Net Cash from Operations | $1.65B | $1.25B | $1.37B | $1.59B | $0.80B |
| Investing Activities | |||||
| Capital Expenditure | ($0.50B) | ($0.50B) | ($0.53B) | ($0.55B) | ($0.56B) |
| Purchases of Investments | ($0.06B) | ($0.07B) | ($0.05B) | ($0.00B) | ($0.05B) |
| Sales of Investments | $0.04B | $0.04B | $0.00B | $0.00B | $0.17B |
| Net Cash from Investing | $0.74B | $0.79B | $0.97B | $0.66B | $1.52B |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($1.81B) | ($1.64B) | ($1.70B) | ($1.37B) | ($2.17B) |
| Net Cash from Financing | ($2.15B) | ($1.79B) | ($1.91B) | ($1.49B) | ($2.17B) |
| Free Cash Flow | |||||
| Free Cash Flow | $1.15B | $0.75B | $0.84B | $1.04B | $0.24B |
| FCF Margin %(computed) | 6.65% | 4.53% | 5.31% | 6.98% | 1.49% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Teva Pharmaceutical Industries Limited data
About Teva Pharmaceutical Industries Limited (TEVA) Cash Flow Statement
Teva Pharmaceutical Industries Limited generated operating cash flow of $1.65B and free cash flow of $1.15B for 2025 — a FCF margin of 6.65%. Capital expenditure was ($0.50B).
Frequently asked questions
TEVA · 4 questionsTeva Pharmaceutical Industries Limited generated free cash flow of $1.15B for 2025, up 53.3% year-over-year.
TEVA free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08